Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated C and is the 74th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
FONR	FONAR CORP	$103.33M	6,585,978	44.38%	3.58%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$7.52B	49,214,178	96.60%	3.40%	Net Buying	Net Selling
SHC	SOTERA HEALTH CO	$4.56B	283,855,074	70.79%	29.21%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$51.29B	80,004,694	92.95%	1.77%	Net Selling	Net Buying
LH	LABCORP HOLDINGS INC	$23.10B	83,100,000	96.22%	1.53%	Net Selling	Net Selling
QGEN	QIAGEN NV	$9.86B	217,685,000	76.05%	0.00%
EXAS	EXACT SCIENCES CORP	$10.21B	189,319,110	94.92%	3.32%	Net Selling	Net Selling
DHR	DANAHER CORP	$136.09B	716,051,590	75.71%	24.29%	Net Selling	Net Buying
A	AGILENT TECHNOLOGIES INC	$34.94B	283,500,427	89.85%	1.24%	Net Buying	Net Buying
WAT	WATERS CORP	$17.58B	59,524,130	92.35%	7.65%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$13.78B	28,093,026	28.62%	71.38%	Net Buying	Net Selling
ILMN	ILLUMINA INC	$14.62B	153,700,000	93.37%	6.63%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$20.45B	111,823,441	95.76%	1.77%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$669.73M	30,609,044	53.12%	42.23%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$25.95B	20,599,040	95.54%	4.46%	Net Selling	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$181.05B	377,612,121	88.72%	0.89%	Net Selling	Net Selling
XGN	EXAGEN INC	$214.32M	22,003,641	41.59%	50.67%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	$1.53B	60,360,925	88.58%	11.42%	Net Selling	Net Selling
RVTY	REVVITY INC	$9.62B	116,072,580	97.29%	2.71%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	$31.83B	170,000,000	53.93%	46.07%	Net Selling	Net Selling
RDNT	RADNET INC	$5.69B	76,916,062	69.79%	30.21%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$673.64M	93,044,627	91.33%	8.67%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	$133.47M	13,247,315	8.71%	0.00%
NEO	NEOGENOMICS INC	$1.03B	129,178,622	72.44%	27.56%	Net Buying	Net Buying
ACRS	ACLARIS THERAPEUTICS INC	$211.15M	108,281,239	58.78%	41.22%	Net Buying
MDXH	MDXHEALTH SA	$18.26M	49,497,334	23.06%	76.94%
GH	GUARDANT HEALTH INC	$6.85B	124,705,857	66.66%	33.34%	Net Selling	Net Selling
NTRA	NATERA INC	$23.01B	136,546,580	80.21%	19.79%	Net Selling	Net Selling
GRAL	GRAIL INC	$1.37B	36,047,799	72.77%	26.25%	Net Buying	Net Selling
ICLR	ICON PLC	$13.61B	77,772,130	97.64%	0.00%
CSTL	CASTLE BIOSCIENCES INC	$621.36M	29,008,281	85.56%	14.44%	Net Selling	Net Selling
STIM	NEURONETICS INC	$206.64M	66,124,820	27.29%	32.68%	Net Selling	Net Selling
LAB	STANDARD BIOTOOLS INC	$492.77M	381,995,102	54.17%	45.83%	Net Buying	Net Buying
CAI	CARIS LIFE SCIENCES INC	$9.58B	281,224,124	33.64%	66.36%	Net Selling	Net Selling
NOTV	INOTIV INC	$48.44M	34,352,978	24.51%	39.38%	Net Buying	Net Selling
SERA	SERA PROGNOSTICS INC	$117.99M	38,061,868	48.89%	25.58%	Net Selling	Net Selling
PSNL	PERSONALIS INC	$518.76M	88,677,062	62.59%	37.41%	Net Selling	Net Selling
CDNA	CAREDX INC	$720.16M	53,226,948	78.08%	21.92%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$10.80M	5,539,345	1.03%	98.97%
NEOG	NEOGEN CORP	$1.19B	217,205,186	98.19%	1.81%	Net Buying	Net Buying
OPK	OPKO HEALTH INC	$1.11B	793,782,780	20.70%	79.30%	Net Buying	Net Buying
APDN	APPLIED DNA SCIENCES INC	$3.46M	1,291,465	0.67%	99.33%
VNRX	VOLITIONRX LTD	$71.01M	107,595,421	22.29%	35.50%	Net Buying	Net Buying
XWEL	XWELL INC	$6.33M	5,756,703	1.23%	98.77%
PRPH	PROPHASE LABS INC	$17.99M	41,541,205	6.45%	24.84%
NDRA	ENDRA LIFE SCIENCES INC	$3.57M	752,755	0.45%	99.55%
PRPO	PRECIPIO INC	$31.58M	1,619,584	0.37%	99.63%	Net Buying	Net Selling
TRIB	TRINITY BIOTECH PLC	$21.37M	359,193,482	0.71%	0.00%
CHEK	CHECK-CAP LTD	$4.36M	5,850,906	2.02%	0.00%
MYNZ	MAINZ BIOMED NV	$3.85M	2,319,353	16.63%	0.00%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$88.15M	28,619,749	15.71%	84.29%	Net Buying
BDSX	BIODESIX INC	$54.96M	146,563,031	24.30%	58.19%	Net Buying	Net Buying
BNR	BURNING ROCK BIOTECH LTD	$89.38M	107,682,818	1.34%	0.00%
ADVB	ADVANCED BIOMED INC	$11.21M	21,640,000	0.61%	0.00%
DRIO	DARIOHEALTH CORP	$16.17M	2,274,848	29.41%	70.59%	Net Buying	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	$7.69M	28,468,612	1.27%	16.89%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -5.2% over the past year, overperforming other diagnostic & research stocks by 16 percentage points.

2. Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Charles River Laboratories International (NYSE:CRL) is: Value: C, Growth: B, Momentum: D, Sentiment: B, Safety: B, Financials: B, and AI: B.

Charles River Laboratories International (NYSE:CRL) has a Due Diligence Score of 14, which is -12 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates CRL as a "A".

CRL passed 4 out of 33 due diligence checks and has weak fundamentals. Charles River Laboratories International has seen its stock lose -21.32% over the past year.

Charles River Laboratories International has an average 1 year price target of $173.00, an upside of 13.15% from Charles River Laboratories International's current stock price of $152.89.

Charles River Laboratories International stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Charles River Laboratories International, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock lose -2.61% over the past year, overperforming other diagnostic & research stocks by 18 percentage points.

Sotera Health Co has an average 1 year price target of $14.33, a downside of -10.7% from Sotera Health Co's current stock price of $16.05.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.28%, which is 1 percentage points higher than the diagnostic & research industry average of 0.65%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.6% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.04%, which is the same as the diagnostic & research industry average of 0.65%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 31.5% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.59%, which is the same as the diagnostic & research industry average of 0.65%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.76% in the last day, and down -1.95% over the last week. Prophase Labs was the among the top losers in the diagnostics & research industry, dropping -15.92% yesterday.

ProPhase Labs shares are trading lower. The company moved forward with its strategic initiatives, including a significant increase in authorized shares to 1 billion.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -41.61% in the past year. It has underperformed other stocks in the diagnostic & research industry by -21 percentage points.

2. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -5.2% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Illumina has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Illumina's stock has dropped -24.66% in the past year. It has underperformed other stocks in the diagnostic & research industry by -4 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 9.75% over the next year.

7.14% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 11.9% of diagnostic & research stocks are rated B (Buy), 64.29% are rated C (Hold), 11.9% are rated D (Sell), and 4.76% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 20.92x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.